Navigation Links
Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Date:12/14/2011

NORWALK, Conn. and SOUTH SAN FRANCISCO, Calif., Dec. 14, 2011 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the start of a multi-year collaboration in support of the comprehensive research initiative in personalized medicine sponsored by the MMRF. The MMRF's Personalized Medicine Initiative, the largest research effort ever undertaken against this incurable disease, is designed to enable the molecular characterization of patients with multiple myeloma and advance the development of new, targeted treatments for the disease.

As a charter member of a growing pre-competitive consortium which includes academic, industry and non-profit members, Onyx, which has a focus in multiple myeloma, will provide scientific and financial support for this comprehensive research initiative. The pre-competitive component of the collaboration gives the consortium equal access to data generated for a set period of time before the data is released in the public domain.

"We look forward to working closely with Onyx to gain a much better understanding of how this disease develops and progresses, and to bring the entire R&D ecosystem together to greatly accelerate the development of new treatments, and ultimately, a cure," said Kathy Giusti, founder and CEO of the MMRF and Multiple Myeloma Research Consortium, and a multiple myeloma patient. "Onyx is an invaluable partner who shares our passion for rapidly translating new insights into breakthrough therapies to bring us closer to a cure. We look forward to working together in this critical initiative."

The MMRF announced earlier this year that enrollment has begun in its CoMMpass(SM) Study (relating Clinical Outcomes in Multiple Myeloma to Personal AsseSSment of genetic profile), the cornerstone of the multiple myeloma personalized medicine research e
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Multiple Myeloma Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... VIEW, Calif., Feb. 10, 2011 ZONARE Medical Systems, ... z.one Ultrasound System to Woodlands Church of Plover, WI, ... the past year, ZONARE has provided six systems to ... and medical missions. Woodlands Church performs annual ...
... AlphaDetail, a leader in global primary market research for ... in revenue in 2010, exceeding $18.5M in annual revenue ... "Our clients have delivered a loud and clear ... get at the heart of their strategic information needs," ...
Cached Medicine Technology:ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 2ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 3AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... Nfocus Neuromedical, Inc.,today announced that the company ... and Delivery System. The CardioVasc(TM),Stent-Graft is a minimally ... Lesions (SVGs) from a previous coronary bypass, Vessel,Perforations ... Nfocus to,begin marketing the CardioVasc(TM) Stent-Graft in the ...
... Division becomes newest reseller ... xTag wireless microphone, MAYNARD, Mass., Feb. 12 ... for enhancing collaboration, today announced,that the Dictaphone Healthcare ... xTag Wireless Microphone alongside its Dragon(R),NaturallySpeaking(R) Medical speech ...
... high-end ,infotainment, systems manufacturer to manage global ... manufacturing operations with Visiprise Manufacturing, ... leader in,integrated manufacturing execution (MES) solutions today ... Harman,International, has selected Visiprise Manufacturing as their ...
... TeamStaff, Inc.,(Nasdaq: TSTF ) a national ... today that it is changing the name ... Inc., to TeamStaff,Government Solutions (dba TeamStaff GS)., ... provides medical, office,administration and logistics professionals through ...
... Mich., Feb. 12 Affiliated Computer,Services, Inc. (ACS) ... Healthcare Solutions -- has earned four no. 1 ... Awards, issued by KLAS Enterprises, LLC., The ... Implementation Principal,Financial Implementation Supportive, Staff Augmentation, and Other,Implementation ...
... AMN Healthcare Services,Inc. (NYSE: AHS ), ... Hala Moddelmog, President and Chief Executive Officer,of Susan ... company,s Board of,Directors., "Hala brings valuable experience ... in the global breast cancer movement and,previously, as ...
Cached Medicine News:Health News:Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 3Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 2Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:ACS is 'Best in KLAS' for Healthcare Consulting Services 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 3
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: